EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Population pharmacokinetics of TBAJ‐587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection

Albin A M Leding, Paul Bruinenberg, Almari Conradie, Jerry Nedelman, Antonio Lombardi, Dean Hickman, Ulrika S H Simonsson iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Albin A M Leding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Antitubercular Agents, Diarylquinolines, Models, Biological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Innovative Medicines Initiative 2 Joint Undertaking (JU).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim The rise of drug‐resistant tuberculosis (TB) poses a need for new drugs and combinations. TBAJ‐587, a new diarylquinoline (DARQ), has shown promising efficacy in preclinical studies. This work aimed to describe the pharmacokinetics (PK) of TBAJ‐587 and its metabolites M2 and M3 after single ascending dosing in healthy volunteers and to develop a simultaneous population PK model. In addition, to explore different doses in relation to efficacy and safety and to assess the impact of loading doses on exposure levels of TBAJ‐587 and its metabolites. Methods Pharmacokinetic samples from 42 healthy volunteers following a single dose (25, 50, 100, 200, 400 or 800 mg) were collected for up to Day 126. Population pharmacokinetic modelling was conducted using nonlinear mixed‐effects modelling in NONMEM. Simulations from final model were performed to compare against efficacy targets derived from the first‐in‐class DARQ bedaquiline and safety references based on preclinical studies. Results and Conclusions The final model simultaneously described the PK of TBAJ‐587, M2 and M3 well. Simulations of final model identified that all simulated doses and regimens resulted in exposures that were below the safety references. A loading dose for 2 weeks resulted in initially higher concentrations, but a limited difference in exposure at 4 weeks and onwards, compared with no loading dose. A 100 mg once daily dose and higher reached the efficacy targets and can be studied further in combinations in phase 2a studies. Name of trial: Evaluation of the Safety, Tolerability, PK of TBAJ‐587 in Healthy Adults. Registration number: NCT04890535.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsDiarylquinolinesModels, BiologicalHumansAdultMaleFemaleYoung AdultHealthy VolunteersDose-Response Relationship, DrugMiddle AgedAdolescentTuberculosis, Multidrug-Resistant

Stichwörter der Autor:innen

TBAJ‐587metabolitepharmacometricspopulation pharmacokineticstuberculosis

Substanzen

Antitubercular AgentsDiarylquinolinesbedaquiline

Autor:innen und Institutionen

  • Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
  • TB Alliance, New York, New York, USA.

ORCID-Profile: Ulrika S H Simonsson

Förderung

  • Innovative Medicines Initiative 2 Joint Undertaking (JU)

Zitieren

APA

Leding, A. A. M., Bruinenberg, P., Conradie, A., Nedelman, J., Lombardi, A., Hickman, D., & Simonsson, U. S. H. (2026). Population pharmacokinetics of TBAJ‐587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70333

Vancouver

Leding AAM, Bruinenberg P, Conradie A, Nedelman J, Lombardi A, Hickman D, et al. Population pharmacokinetics of TBAJ‐587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70333

BibTeX
@article{Leding2026,
  author = {Leding, Albin A M and Bruinenberg, Paul and Conradie, Almari and Nedelman, Jerry and Lombardi, Antonio and Hickman, Dean and Simonsson, Ulrika S H},
  title = {Population pharmacokinetics of TBAJ‐587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70333}
}
Kostenlos starten →